These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 17401513

  • 1. Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Balbir-Gurman A, Braun-Moscovici Y, Livshitz V, Schapira D, Markovits D, Rozin A, Boikaner T, Nahir AM.
    Clin Rheumatol; 2007 Sep; 26(9):1517-21. PubMed ID: 17401513
    [Abstract] [Full Text] [Related]

  • 2. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels.
    Mittag M, Beckheinrich P, Haustein UF.
    Acta Derm Venereol; 2001 Sep; 81(4):294-7. PubMed ID: 11720181
    [Abstract] [Full Text] [Related]

  • 3. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
    Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E, Arpaia G, Sardina M, Origgi L, Vanoli M.
    Clin Exp Rheumatol; 2001 Sep; 19(5):503-8. PubMed ID: 11579708
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of oral iloprost in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Janssena MC, Wollersheim H, Kraus C, Hildebrand M, Watson HR, Thien T.
    Prostaglandins Other Lipid Mediat; 2000 Mar; 60(4-6):153-60. PubMed ID: 10751645
    [Abstract] [Full Text] [Related]

  • 6. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
    Bettoni L, Geri A, Airò P, Danieli E, Cavazzana I, Antonioli C, Chiesa L, Franceschini F, Grottolo A, Zambruni A, Radaeli E, Cattaneo R.
    Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
    [Abstract] [Full Text] [Related]

  • 7. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A, Burmester GR, Huscher D, Sunderkötter C, Riemekasten G.
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [Abstract] [Full Text] [Related]

  • 8. Discontinuing long-term Iloprost treatment for Raynaud's Phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study.
    Bali G, Schwantzer G, Aberer F, Kraenke B, Aberer E.
    Acta Dermatovenerol Alp Pannonica Adriat; 2011 Sep; 20(1):13-21. PubMed ID: 21879200
    [Abstract] [Full Text] [Related]

  • 9. The safety and persistence of intravenous iloprost in systemic sclerosis.
    Martins P, Dourado E, Fonseca JE, Romão V, Resende C.
    ARP Rheumatol; 2022 Sep; 1(2):122-128. PubMed ID: 35810370
    [Abstract] [Full Text] [Related]

  • 10. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
    Gardinali M, Pozzi MR, Bernareggi M, Montani N, Allevi E, Catena L, Cugno M, Bottasso B, Stabilini R.
    J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
    [Abstract] [Full Text] [Related]

  • 11. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E, Virgilio S, Ghirardi R, Martinelli M.
    Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
    [Abstract] [Full Text] [Related]

  • 12. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study.
    Pamuk GE, Turgut B, Pamuk ON, Vural O, Demir M, Cakir N.
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):297-302. PubMed ID: 17473568
    [Abstract] [Full Text] [Related]

  • 13. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A, Abou-Raya S, Helmii M.
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [Abstract] [Full Text] [Related]

  • 14. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
    Ingegnoli F, Schioppo T, Allanore Y, Caporali R, Colaci M, Distler O, Furst DE, Hunzelmann N, Iannone F, Khanna D, Matucci-Cerinic M.
    Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
    [Abstract] [Full Text] [Related]

  • 15. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP.
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [Abstract] [Full Text] [Related]

  • 16. Evidence for increase in finger blood flow, evaluated by laser Doppler flowmetry, following iloprost infusion in patients with systemic sclerosis: a week-long observational longitudinal study.
    Rotondo C, Nivuori M, Chialà A, Praino E, Matucci Cerinic M, Cutolo M, Lapadula G, Iannone F.
    Scand J Rheumatol; 2018 Jul; 47(4):311-318. PubMed ID: 29409385
    [Abstract] [Full Text] [Related]

  • 17. The cardiac magnetic resonance in the diagnosis of cardiac Raynaud phenomenon in a patient with systemic sclerosis: case report and review of literature.
    Quarta S, Galea N, Gigante A, Romaniello A, Rosato E, Carbone I.
    Expert Rev Clin Immunol; 2016 Jul; 12(3):251-5. PubMed ID: 26692357
    [Abstract] [Full Text] [Related]

  • 18. Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.
    Cestelli V, Manfredi A, Sebastiani M, Praino E, Cannarile F, Giuggioli D, Ferri C.
    Mod Rheumatol; 2017 Jan; 27(1):110-114. PubMed ID: 27310203
    [Abstract] [Full Text] [Related]

  • 19. The impact of smoking status on antioxidant enzyme activity and malondialdehyde levels in chronic periodontitis.
    Tonguç MÖ, Öztürk O, Sütçü R, Ceyhan BM, Kılınç G, Sönmez Y, Yetkin Ay Z, Sahin U, Baltacıoğlu E, Kırzıoğlu FY.
    J Periodontol; 2011 Sep; 82(9):1320-8. PubMed ID: 21219099
    [Abstract] [Full Text] [Related]

  • 20. Antioxidant effect of Iloprost: current knowledge and therapeutic implications for systemic sclerosis.
    Erre GL, Passiu G.
    Reumatismo; 2009 Sep; 61(2):90-7. PubMed ID: 19633795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.